ASCO '23 Entrees
OncoPharm
00:00
The Benefits of OC Mertinib in Metastatic Breast Cancer
OC Mertinib didn't make a difference in metastatic breast cancer, but it's going to be an overall survival benefit is published in the New England Journal of Medicine. All the guidelines are going to put it as a category one recommendation because of this overall survival benefit. But we don't know if it prolongs overall survival compared to what we would do, which is give them OC MertinIB at the sign of disease recurrence initially. That's our need to know about it.
Transcript
Play full episode
